



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: November 2, 2005

Signature:

Shawn P. Foley
(Shawn P. Foley)

Docket No.: REGIM 3.3-026
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Gamelin et al.

Application No.: 10/501,318

Group Art Unit: 1632

Filing Date: February 25, 2005

Examiner: Not Yet Assigned

For: PROTECTION AGAINST THE
NEUROTOXICITY OF OXALIPLATIN
THROUGH THE ADMINISTRATION OF
CALCIUM AND MAGNESIUM

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:


Applicants respectfully request that the publications listed on the enclosed Form PTO-1449 be made of record and considered with respect to the above-referenced U.S. patent application. A copy of each publication is enclosed. A copy of the corresponding International Search Report is also enclosed. Submission of the present Information Disclosure Statement should not be taken as an admission that the cited publications are legally available prior art or that the same are pertinent or material.

In the event that any fee is due in connection with the present Information Disclosure Statement, the Commissioner is hereby authorized to charge the same to our Deposit Account No. 12-1095.

Dated: November 2, 2005

Respectfully submitted,

By *Shawn P. Foley*
Shawn P. Foley
Registration No.: 33,071
LERNER, DAVID, LITTENBERG,
KRUMHOLZ & MENTLIK, LLP
600 South Avenue West
Westfield, New Jersey 07090
(908) 654-5000
Attorney for Applicant



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/501,318-Conf. #6122	
			Filing Date	February 25, 2005	
			First Named Inventor	Laurence Gamelin	
			Art Unit	1632	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	REGIM 3.3-026

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
	BA	WO-01/74368-A1	10-11-2001	Angiogene Pharmaceuticals		√
	BB	WO-01/08693-A2	02-08-2001	Tularik		√

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	CA	GROLLEAU et al., "A Possible Explanation for a Neurotoxic Effect of the Anticancer Agent Oxaliplatin on Neuronal Voltage-Gated Sodium Channels", Journal of Neurophysiology, Vol 85, No. 5, pgs 2293-2297, 2001			
	CB	BERTHEAULT-CVITKOVIC et al., "Biweekly Intensified Ambulatory Chronomodulated Chemotherapy With Oxaliplatin, Fluororacil, and Leucovorin in Patients With Metastatic Colorectal Cancer", J. Clin. Oncol., Vol. 14, No. 11, pgs. 2950-2958, 1996			
	CC	MACHOVER et al., "Two Consecutive phase II studies of oxaliplatin (I-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines", Annals of Oncology, Vol. 7, pgs 95-98, 1996			
	CD	MOLLMAN, Cisplatin Neurotoxicity, New England Journal of Medicine, Vol. 322, pgs. 126-127, 1990			
	CE	HAGLER et al., "Oxalate metabolism.IV1", The American Journal of Clinical Nutrition, Vol. 26, No. 9, pgs. 1073-1079, September 1973			
	CF	RIZZO et al., "Mechanisms of Paresthesiae, Dysesthesiae, and Hyperesthesiae: Role of Na ⁺ Channel Heterogeneity", European Neurology, Vol. 36, pgs 3-12, 1996			
	CG	Sweg-Hsien et al., "Indinavir urolithiasis", Current Opinion in Urology, Vol. 10, No. 6, pgs. 557-561, 2000			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

606797.1

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--